A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.

Trial Details

NCT ID
NCT05482568
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tes…
  • When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation
  • The ECOG score is 0 or 1
  • The expected survival is ≥12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →